Molecular targeted therapy for HER-2 negative gastric cancer

Molecular targeted treatment has become hotspot in the gastric cancer research. Human epidermal growth factor receptor-2(HER-2) target genes found to treatment has widely used in clinical practice, and HER-2 positive incidence of less than 20%. In addition to HER-2, understanding the molecular pathways that characterize in cell growth, invasion and angiogenesis of targets and targeted therapy are worthy for attention.There are some molecular targeted drugs have been used to treat tumors, and patients can benefit from the treatment which brings new hope for patients with HER-2 negative gastric cancer. Key words: Stomach neoplasms; Receptor, epidermal growth factor; Molecular targeted therapy